Ignite Creation Date:
2024-05-06 @ 4:15 PM
Last Modification Date:
2024-10-26 @ 2:06 PM
Study NCT ID:
NCT04920578
Status:
TERMINATED
Last Update Posted:
2024-03-15
First Post:
2021-06-08
Brief Title:
A Study of JNJ-69095897 in Healthy Participants
Sponsor:
Janssen Research Development LLC
Organization:
Janssen Research Development LLC
Study Overview
Official Title:
A 3-Part Randomized Placebo-controlled Double-blind Single Ascending Dose Study to Investigate Safety and Tolerability Pharmacokinetics and Pharmacodynamics of JNJ-69095897 in Healthy Participants
Status:
TERMINATED
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
business decision to end clinical development of JNJ-69095897
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate the safety and tolerability of JNJ-69095897 versus placebo and to characterize the pharmacokinetic PK of JNJ-69095897 in blood plasma cerebrospinal fluid CSF and urine after single or divided oral dose administration in healthy participants
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2021-000609-26 | EUDRACT_NUMBER | None | None |
| 69095897EDI1001 | OTHER | Janssen Research Development LLC | None |